Bone marrow CD34 positive cells may be suitable for collection after death

被引:3
作者
Rafat, Ali [1 ,2 ]
Asl, Khadijeh Dizaji [1 ,3 ]
Mazloumi, Zeinab [2 ,4 ]
Samadirad, Bahram [5 ]
Ashrafianbonab, Fereidoun [6 ]
Farahzadi, Raheleh [7 ]
Charoudeh, Hojjatollah Nozad [8 ]
机构
[1] Tabriz Univ Med Sci, Fac Med, Dept Anat Sci, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Islamic Azad Univ, Fac Med, Dept Histopathol & Anat, Tabriz Branch, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Appl Cell Sci, Tabriz, Iran
[5] Iranian Legal Med Org, Legal Med Res Ctr, Tehran, Iran
[6] East Azerbaijan Legal Med, Tabriz, Iran
[7] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Tabriz, Iran
[8] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran,
关键词
Hematopoietic stem cells (HSCs); CD34; marker; Oxygen tension; Death individual; HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELLS; GROWTH-FACTOR; PROLIFERATION; GENERATION; SURVIVAL;
D O I
10.1016/j.transci.2022.103452
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematopoietic stem cells (HSCs) which are characterized with CD34+ phenotype, have a pivotal role in blood cell regeneration. They are located in lowest hypoxic areas in the bone marrow niches. This microenvironment protects them from DNA damage and excessive proliferation, whereas the oxygenated area driving cells out of quiescent state into proliferation. Given the resistance of HSCs to hypoxia, it is reasonable to imagine that they can survive for some time in the absence of oxygen. Here, we evaluated CD34, Bax, Bcl-2, Bcl-xl, and p53 genes expression after death. Moreover, we established the ex-vivo development of HSCs using SCF, FLT3, IL-2, and IL15 cytokines in culture system. Our finding indicated that although the most of the dead person's mononuclear cells were alive and adequately expressed the CD34 on their surfaces at the first day of isolation, the viability and CD34+/Ki-67 expression declined significantly after culture process. Taken together, our finding indicated that the viability and CD34+ expression was acceptable on day 0 and could be used as a novel method for therapeutic purposes.
引用
收藏
页数:5
相关论文
共 26 条
[1]  
Andrews RG, 1992, CD34 MARROW CELLS DE
[2]   Regulation of hematopoietic stem cells by bone marrow stromal cells [J].
Anthony, Bryan A. ;
Link, Daniel C. .
TRENDS IN IMMUNOLOGY, 2014, 35 (01) :32-37
[3]   The Effect of Telomerase Inhibition on NK Cell Activity in Acute Myeloid Leukemia [J].
Asl, Khadijeh Dizaji ;
Rafat, Ali ;
Movassaghpour, Ali Akbar ;
Charoudeh, Hojjatollah Nozad ;
Nasrabadi, Hamid Tayefi .
ADVANCED PHARMACEUTICAL BULLETIN, 2023, 13 (01) :170-175
[4]   The role of KIR positive NK cells in diseases and its importance in clinical intervention [J].
Asl, Khadijeh Dizaji ;
Velaei, Kobra ;
Rafat, Ali ;
Nasrabadi, Hamid Tayefi ;
Movassaghpour, Ali Akbar ;
Mahdavi, Majid ;
Charoudeh, Hojjatollah Nozad .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
[5]  
Asl KD, 2017, WORLD J PLAST SURG, V6, P33
[6]   Osteoblastic cells regulate the haematopoietic stem cell niche [J].
Calvi, LM ;
Adams, GB ;
Weibrecht, KW ;
Weber, JM ;
Olson, DP ;
Knight, MC ;
Martin, RP ;
Schipani, E ;
Divieti, P ;
Bringhurst, FR ;
Milner, LA ;
Kronenberg, HM ;
Scadden, DT .
NATURE, 2003, 425 (6960) :841-846
[7]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[8]   Hematopoietic stem cell quiescence maintained by p21cip1/waf1 [J].
Cheng, T ;
Rodrigues, N ;
Shen, HM ;
Yang, YG ;
Dombkowski, D ;
Sykes, M ;
Scadden, DT .
SCIENCE, 2000, 287 (5459) :1804-1808
[9]  
DELLOSBARBA P, 1987, EXP HEMATOL, V15, P137
[10]   HEMATOPOIETIC-CELL GROWTH-FACTOR AND GLUCOSE-TRANSPORT - ITS ROLE IN CELL-SURVIVAL AND THE RELEVANCE OF THIS IN NORMAL HEMATOPOIESIS AND LEUKEMIA [J].
DEXTER, TM ;
WHETTON, AD ;
BAZILL, GW .
DIFFERENTIATION, 1984, 27 (03) :163-167